Myovant Sciences Ltd
NYSE:MYOV
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Myovant Sciences Ltd
Myovant Sciences Ltd
Total Current Liabilities
Myovant Sciences Ltd
Total Current Liabilities Peer Comparison
CNTA
AUTL
BCYC
IMCR
GNS
Competitive Total Current Liabilities Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Myovant Sciences Ltd
NYSE:MYOV
|
Total Current Liabilities
$245.8m
|
CAGR 3-Years
66%
|
CAGR 5-Years
56%
|
CAGR 10-Years
N/A
|
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Total Current Liabilities
$39.4m
|
CAGR 3-Years
66%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Total Current Liabilities
$44.7m
|
CAGR 3-Years
10%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Total Current Liabilities
$49.5m
|
CAGR 3-Years
34%
|
CAGR 5-Years
43%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Total Current Liabilities
£139m
|
CAGR 3-Years
36%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Total Current Liabilities
£128.9m
|
CAGR 3-Years
2%
|
CAGR 5-Years
7%
|
CAGR 10-Years
6%
|
See Also
What is Myovant Sciences Ltd's Total Current Liabilities?
Total Current Liabilities
245.8m
USD
Based on the financial report for Dec 31, 2022, Myovant Sciences Ltd's Total Current Liabilities amounts to 245.8m USD.
What is Myovant Sciences Ltd's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
56%
Over the last year, the Total Current Liabilities growth was -9%. The average annual Total Current Liabilities growth rates for Myovant Sciences Ltd have been 66% over the past three years , 56% over the past five years .
You don't have any saved screeners yet
